MYRIAD GENETICS INC. - COMMON STOCK

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

28 Feb 2023 15:05:01 By Nasdaq GlobeNewswire

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

22 Feb 2023 06:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Participate in Upcoming Healthcare Conferences

09 Feb 2023 06:15:00 By Nasdaq GlobeNewswire

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

07 Feb 2023 06:15:00 By Nasdaq GlobeNewswire

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

05 Jan 2023 06:05:00 By Nasdaq GlobeNewswire

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 07:00:01 By Nasdaq GlobeNewswire

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

19 Dec 2022 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

08 Dec 2022 18:15:00 By Nasdaq GlobeNewswire

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

29 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

17 Nov 2022 06:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

14 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

10 Nov 2022 07:00:03 By Nasdaq GlobeNewswire

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

03 Nov 2022 17:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

01 Nov 2022 08:10:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Third Quarter Financial Results

01 Nov 2022 08:05:01 By Nasdaq GlobeNewswire

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

31 Oct 2022 15:30:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

26 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

28 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

25 Aug 2022 15:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

16 Aug 2022 00:05:00 By Nasdaq GlobeNewswire